Renal Denervation

Forecasting the renal denervation market is a big challenge for medtech marketers. DRG cardiovascular expert Sean Messenger shares four key considerations to plan an accurate market forecast.   Transcription: Forecasting the renal denervation market is definitely a challenge. There are four...

The renal denervation market will see significant development after the first device is approved by the FDA. DRG cardiovascular expert Sean Messenger reviews: What key factors that will influence the market Implications for new players entering the space Transcription: So, given the recent clinical...

The renal denervation market has evolved dramatically over recent years. DRG cardiovascular expert Sean Messenger discusses: Major changes between five years ago and today How those changes have impacted clinical trials Transcription: So, today the renal denervation clinical landscape is quite...

In the latest post of this series, we provided an overview on the story of renal denervation and an update on the latest developments in this technology. In brief, though results from the Symplicity HTN-3 trial were disappointing and led to a pause on progress in this field in 2014, more recent...

The story of renal denervation and its spectacular and shocking failure in 2014 is one of the more dramatic narratives in the medical device industry, and one that we at DRG Medtech (and I personally) have been following closely for more than 6 years. With the publication of positive clinical trial...

I promise I care about non-renal denervation medical devices. Really, I do. But this area is just so dynamic that it keeps drawing my attention. So be it. I was there, sitting in the main presentation hall at the Walter E Washington Convention Center, when the

Renal denervation was the single hottest topic in cardiovascular medtech for two years, the star prospect of an industry hungry for growth stories. That, however, was before negative results of the pivotal SYMPLICITY HTN-3 trial were announced in January 2014 ...

This morning, an announcement from Medtronic rocked one of the hottest markets in medtech: renal denervation, the device-based treatment for hypertension. Medtronic announced that the results from its SYMPLICITY HTN-3 trial failed to meet its primary efficacy ...

As we mentioned in an earlier post, renal denervation was set to be one of the biggest trends in medtech in 2012, and it hasn?t failed us. It's been a hot topic at numerous conferences this year, including the

I think we can all agree that as we come out of a rough 2011 for medtech, a number of questions are weighing on everyone's minds for 2012. How will fears of a second recession and growing problems in the troubled European economies affect medtech? What new emerging technologies have great potential...